Veru (NASDAQ:VERU) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.30) by 70 percent. This is a 920 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $2.59 million in sales this quarter. This is a 83.45 percent decrease over sales of $15.65 million the same period last year.
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and AstraZeneca Plc (NASDAQ:AZN) announced that the Phase 3 NEURO-TTRansform study for eplontersen in patients with hereditary…
